F. Azab

发表

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Charles P. Lin, Kwok-Kin Wong, A. Roccaro, 2010, Blood.

B in Waldenstrom macroglobulinemia κ Targeting NF

D. Carrasco, K. Anderson, J. Eeckhoute, 2013 .

Targeting NF-B in Waldenstrom macroglobulinemia

D. Carrasco, K. Anderson, Myles A Brown, 2008 .

Targeting NF-kappaB in Waldenstrom macroglobulinemia.

D. Carrasco, K. Anderson, J. Eeckhoute, 2008, Blood.

1 Targeting NF-κ B in Waldenstrom Macroglobulinemia

D. Carrasco, K. Anderson, J. Eeckhoute, 2008 .

Defining the role of TORC1/2 in multiple myeloma.

Charles P. Lin, C. Rommel, S. Rodig, 2011, Blood.

The bone marrow microenvironment in Waldenstrom macroglobulinemia

A. Roccaro, A. Sacco, A. Azab, 2011, Therapeutic advances in hematology.

Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia

K. Anderson, A. Roccaro, A. Sacco, 2009, Clinical Cancer Research.

Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in Waldenström Macroglobulinemia

A. Azab, F. Azab, I. Ghobrial, 2014, Molecular Cancer Research.

Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features.

Charles P. Lin, A. Kung, A. Roccaro, 2011, Blood.

FGFR3 Is Overexpressed Waldenström Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation

A. Roccaro, A. Sacco, A. Azab, 2011, Clinical Cancer Research.

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.

K. Anderson, S. Demo, M. Aujay, 2010, Blood.

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

S. Achilefu, D. Hallahan, R. Vij, 2020, Nature Communications.

Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

M. Aujay, A. Roccaro, A. Sacco, 2011, Clinical Cancer Research.

CXCR4-targeted PET imaging using 64Cu-AMD3100 for detection of Waldenström Macroglobulinemia

A. Azab, F. Azab, B. Rogers, 2020, Cancer biology & therapy.

Targeting the bone marrow in Waldenstrom macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2011, Clinical lymphoma, myeloma & leukemia.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

K. Anderson, P. Richardson, S. Rodig, 2013, Blood.

macroglobulinemia SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom

A. Roccaro, A. Sacco, A. Azab, 2013 .

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2008, Blood.

Inhibition of P-Selectin and PSGL-1 Using Humanized Monoclonal Antibodies Increases the Sensitivity of Multiple Myeloma Cells to Bortezomib

A. Azab, F. Azab, R. Alvarez, 2015, BioMed research international.

P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment.

Charles P. Lin, A. Letai, A. Kung, 2012, Blood.

acquisition of epithelial to mesenchymal transition-like features Hypoxia promotes dissemination of multiple myeloma through

Charles P. Lin, A. Kung, A. Roccaro, 2012 .

myeloma cells with the bone marrow microenvironment P-selectin glycoprotein ligand regulates the interaction of multiple

Charles P. Lin, A. Letai, A. Kung, 2012 .

Cancer Therapy: Preclinical Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

M. Aujay, A. Roccaro, A. Sacco, 2011 .

A CD138‐independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma

R. Vij, A. Azab, F. Azab, 2016, British journal of haematology.

Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

A. Roccaro, A. Sacco, A. Azab, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Mechanisms of Activity of the TORC 1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

A. Roccaro, A. Sacco, A. Azab, 2012 .

Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia

P. Richardson, S. Rodig, L. Varticovski, 2010, Clinical Cancer Research.

Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan‐class I PI3K inhibitor, buparlisib

A. Roccaro, A. Sacco, A. Azab, 2014, American journal of hematology.

The bone marrow niche in Waldenström's macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2011, Clinical lymphoma, myeloma & leukemia.

PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma

R. Vij, D. Weaver, A. Azab, 2019, Haematologica.

Hypoxia promotes stem cell-like phenotype in multiple myeloma cells

A. Azab, F. Azab, B. Muz, 2014, Blood Cancer Journal.

Rho-a and Rac-1 GTPases Play Major and Differential Roles in SDF1α- Induced Cell Adhesion and Chemotaxis in Multiple Myeloma.

Charles P. Lin, A. Roccaro, A. Sacco, 2008 .

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy

Abdel Kareem Azab, Barbara Muz, A. Azab, 2015, Hypoxia.

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma

J. Arbiser, A. Azab, F. Azab, 2015, Leukemia & lymphoma.

3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma.

S. Achilefu, R. Vij, A. Azab, 2015, Biomaterials.

LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.

S. Kauppinen, S. Fernandes, S. Obad, 2012, Blood.

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

D. Scadden, Y. Tai, A. Roccaro, 2013, The Journal of clinical investigation.

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.

J. Carpten, J. Keats, P. L. Bergsagel, 2009, Cancer research.

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma

B. Rollins, A. Roccaro, A. Sacco, 2013, PloS one.

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2010, Blood.

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Charles P. Lin, B. Rollins, D. Ribatti, 2009, Blood.

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

D. Chauhan, S. Treon, T. Hideshima, 2008, Blood.

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Charles P. Lin, B. Rollins, A. Roccaro, 2009, Blood.

Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis.

A. Roccaro, A. Sacco, A. Azab, 2011, Clinical lymphoma, myeloma & leukemia.

PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma‐induced resistance

R. Vij, A. Azab, F. Azab, 2014, British journal of haematology.

Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination

A. Sacco, F. Azab, P. Maiso, 2014, Blood Cancer Journal.

The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies

A. Azab, F. Azab, B. Muz, 2014, Molecular Cancer Research.

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

B. Rollins, L. Varticovski, A. Roccaro, 2009, Blood.

Inhibition of E-Selectin (GMI-1271) or E-selectin together with CXCR4 (GMI-1359) re-sensitizes multiple myeloma to therapy

R. Vij, A. Azab, F. Azab, 2019, Blood Cancer Journal.

Role of proteasome inhibition in Waldenström's macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2009, Clinical lymphoma & myeloma.

Novel therapeutic agents in Waldenström's macroglobulinemia.

A. Roccaro, A. Sacco, Emanuel N. Husu, 2009, Clinical lymphoma & myeloma.

The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.

A. Roccaro, A. Sacco, A. Azab, 2009 .

Dual Targeting of -TORC1 and -TORC2 as a New Strategy In the Treatment of Multiple Myeloma

C. Rommel, A. Roccaro, A. Sacco, 2010 .

Molecularly Targeted Therapies in Multiple Myeloma

A. Azab, F. Azab, B. Muz, 2014, Leukemia Research and Treatment.

Cell Trafficking of Endothelial Progenitor Cells in Tumor Progression

A. Azab, F. Azab, B. Muz, 2013, Clinical Cancer Research.

Heparin Can Prevent Them Selectins Facilitate Carcinoma Metastasis and

Charles P. Lin, A. Kung, A. Roccaro, 2015 .

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Charles P. Lin, B. Rollins, N. Munshi, 2009, Blood.

A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma

R. Vij, J. Dipersio, A. Azab, 2021, Scientific Reports.

Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma

A. Azab, F. Azab, Y. Landesman, 2017, Translational oncology.

Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance

R. Vij, A. Azab, F. Azab, 2017, Leukemia & lymphoma.

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma

A. Azab, F. Azab, N. N. Salama, 2016, Blood Cancer Journal.

The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression

A. Azab, F. Azab, I. Ghobrial, 2013, Leukemia.

In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.

Charles P. Lin, A. Kung, C. Pitsillides, 2007 .

Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom's Macroglobulinemia

T. Calimeri, A. Roccaro, A. Sacco, 2011, Clinical Cancer Research.

Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma

Y. Tai, A. Roccaro, A. Sacco, 2011 .

B622 Rho-A and Rac-1 GTPases in Multiple Myeloma

Charles P. Lin, Melhem, A. Roccaro, 2009 .

Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.

M. Dyer, S. O’Rahilly, N. Wareham, 2009, The Journal of clinical investigation.

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy.

A. Azab, F. Azab, B. Muz, 2015 .

Digital Commons

A. Azab, F. Azab, B. Muz, 2022 .

microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia.

A. Roccaro, A. Sacco, A. Azab, 2010, Blood.

A. Sacco, F. Azab, J. Runnels, 2008 .

The role of hypoxia in cancer progression , angiogenesis , metastasis , and resistance to therapy

A. Azab, F. Azab, B. Muz, 2016 .

Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma

J. Arbiser, A. Azab, F. Azab, 2016, Leukemia & lymphoma.

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma

B. Rollins, A. Roccaro, A. Sacco, 2013, PloS one.

Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia

M. Aujay, A. Roccaro, A. Sacco, 2011, Clinical Cancer Research.

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

P. Richardson, S. Rodig, F. Azab, 2013, Blood.

Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia

A. Roccaro, A. Sacco, A. Azab, 2012, Clinical Cancer Research.

CLINICAL TRIALS AND OBSERVATIONS Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia

P. Richardson, F. Azab, I. Ghobrial, 2017 .

Mechanisms of activity of the TORC1 inhibitor everolimus in Waldesntrom’s macroglobulinemia

A. Sacco, A. Azab, F. Azab, 2012 .

The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy

A. Azab, F. Azab, B. Muz, 2015, Hypoxia.

Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.

Charles P. Lin, A. Roccaro, A. Sacco, 2010, Blood.

Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.

S. Demo, M. Aujay, A. Roccaro, 2009 .

Buparlisib (NVP-BKM-120)

A. Azab, F. Azab, N. N. Salama, 2013, Drugs of the Future.